Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells
and either kill them or deliver tumor-killing substances to them without harming normal
cells.
PURPOSE: Phase I trial to study the effectiveness of vinorelbine plus trastuzumab in treating
patients who have refractory or metastatic breast cancer.